Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Active topical NS2 1% dermatologic cream, Active NS2 1% dermatologic, NS2 Ophthalmic Drops (0.5%)
NS2 · 3 trials · 4 indications
Mean change from baseline in ocular itching score using a 0 to 4 scale (0 = none, 4 = severe) on Day 14, 60 minutes into the allergen challenge. The least squares mean (standard error) was derived from analysis of covariance (ANCOVA) with baseline as a covariate and treatment group as a factor.
Change from baseline comparison of NS2 ophthalmic drops (0.5%), NS2 (0.5%) and Pred Forte® (0.1%) ophthalmic drops, and Pred Forte® (1%) ophthalmic drops on an anterior chamber cell grade scale of 0 to 4 (0 = absent, 4 = severe). The least squares mean (standard error) was derived from analysis of covariance (ANCOVA) with baseline as a covariate and treatment group as a factor.
| Arm | Type | Description |
|---|---|---|
| NS2 Ophthalmic Drops (0.5%) | EXPERIMENTAL | NS2 Ophthalmic Drops (0.5%) |
| NS2 Ophthalmic Drops Vehicle (0.0%) | SHAM_COMPARATOR | NS2 Ophthalmic Drops Vehicle (0.0%) control |
| Active topical NS2 1% dermatologic cream | EXPERIMENTAL | NS2 1% topical cream for dermal application |
| Topical vehicle dermatologic | PLACEBO_COMPARATOR | Vehicle placebo for dermal application |
| NS2 | EXPERIMENTAL | NS2 ophthalmic drops (0.5%) in the affected eye |
| NS2 and Pred Forte | EXPERIMENTAL | NS2 ophthalmic drops (0.5%) and Prednisolone acetate ophthalmic suspension (1%) in the affected eye |
| Pred Forte | ACTIVE_COMPARATOR | Prednisolone acetate ophthalmic suspension (1%) in the affected eye |
| Name | Type | Description |
|---|---|---|
| NS2 Ophthalmic Drops (0.5%) | DRUG | - |
| NS2 Ophthalmic Drops Vehicle (0.0%) | DRUG | - |
| Active topical NS2 1% dermatologic cream | DRUG | - |
| Vehicle placebo 0.0% NS2 dermatologic cream | DRUG | - |
| NS2 | DRUG | NS2 ophthalmic drops (0.5%) |
| Prednisolone acetate ophthalmic suspension (1%) | DRUG | - |
Inclusion Criteria: * Graded conjunctival redness in at least one region (nasal or temporal) in each eye at any one time point (not necessarily the same time point) post-CAPT (Conjunctival Allergen Provocation Test) of \>2 * Graded ocular itching at any one time point * Visual acuity of at least 20...
NS2 is an investigational small molecule developed by Aldeyra Therapeutics, Inc. (ticker ALDX) for ophthalmic and dermatologic conditions. It is being studied in allergic conjunctivitis, non-infectious anterior uveitis, and Sjögren-Larsson syndrome. NS2 is in Phase 2 clinical development and has not been approved by the FDA.
NS2 is being developed for allergic conjunctivitis, non-infectious anterior uveitis, and Sjögren-Larsson syndrome. These are the three indications studied in its completed Phase 2 trials. NS2 is investigational and is not approved for any use.
NS2 is developed by Aldeyra Therapeutics, Inc., which trades on the Nasdaq under the ticker ALDX. The company is the sponsor of the clinical trials evaluating NS2 in allergic conjunctivitis, non-infectious anterior uveitis, and Sjögren-Larsson syndrome.
NS2 is in Phase 2 clinical development. All three of its completed trials were Phase 2 studies. NS2 is investigational and has not been approved by the FDA for any indication.
NS2 has been studied in three completed Phase 2 trials: NCT02578914 in allergic conjunctivitis, NCT02406209 in non-infectious anterior uveitis, and NCT02402309 in Sjögren-Larsson syndrome. All three trials are completed, and no active trials are currently listed.
Yes, NS2 is also known as Active topical NS2 1% dermatologic cream, Active NS2 1% dermatologic, and NS2 Ophthalmic Drops (0.5%). These names refer to the same investigational small molecule developed by Aldeyra Therapeutics for ophthalmic and dermatologic indications.